Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.
Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.
Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.
Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.
Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of the Swiss drugmaker’s $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin.
Amgen Inc. reported fourth-quarter 2018 profit that easily surpassed expectations as sales rose and tax expense fell, but competition for the company’s older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.
Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
Abbott’s fourth-quarter 2018 revenue fell short of Wall Street expectations due to lower sales of generic drugs in emerging markets as well as a strong dollar, and the healthcare company forecast first-quarter 2019 earnings below analysts’ estimates.
Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.